Clinical trials with halofantrine hydrochloride in Malawi.
Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/microliter to 212,000/microliter. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic--ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparum chloroquine sensitive and resistant strains in Africa.
D000284:Administration, Oral; D000293:Adolescent; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008288:Malaria / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D008295:Malawi; D008297:Male; D010616:Phenanthrenes / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D010963:Plasmodium falciparum; D012008:Recurrence; D013997:Time Factors
D000962:Antimalarials; D010616:Phenanthrenes; D002738:Chloroquine; C023768:halofantrine